🟢 Lipocine is trading 6.54% up today amid a 2.09% biotech sector gain

Lipocine is trading at $1.63, up +6.54%, with broader biotech-sector strength potentially contributing to the move.

• No new company-specific announcement was found for October 20; Lipocine’s latest listed release was the October 7 Health Canada approval of TLANDO.
• The broader biotech sector is up 2.09%, supported by M&A activity and anticipation of cancer data.
• Trading-volume information was not available in the provided price context, so activity levels cannot be assessed.